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Drug reaction with eosinophilia and systemic symptoms 
(DRESS) is a T cell–mediated, delayed-type hypersensitivity 
reaction and, consequently, a severe cutaneous adverse 
reaction (SCAR). It is characterized by the combination of 
skin rash, fever, eosinophilia and other blood abnormalities, 
lymphadenopathy, and multiorgan involvement [1,2]. DRESS 
is unique in that it has a long latency period (2-8 weeks) 
between drug exposure and symptoms, as well as a long 
disease course with frequent flare-ups despite discontinuation 
of the suspected culprit drug. DRESS is rare, and its incidence 
and prevalence are unknown. It has been associated with a 
mortality rate of 5%-10% [1], although some studies have 
reported lower rates [2,3].
Multiple-drug hypersensitivity syndrome (MDHS) is 
characterized by sensitization to ≥2 chemically unrelated 
drugs [4]. DRESS is the SCAR most frequently associated 
with MDHS, which can complicate up to 18% of cases of 
DRESS [5]. MDHS can be distinguished from DRESS flare-
ups by the presence of sensitization to multiple drugs proven 
by skin or in vitro tests [4].
We report the case of a 37-year-old woman who was 
admitted to the pulmonology department with high fever 
and pulmonary infiltrates and left pleural effusion, which 
were described in the CT scan as “loculated empyema 
with gas inside, suggesting dense exudate”. Her previous 
history included tuberculosis at 12 years of age, which was 
uneventfully treated with isoniazid, rifampicin, pyrazinamide, 
and ethambutol (HRZE). Five months earlier, she had also been 
diagnosed with severe depression, for which she was taking 
olanzapine, sertraline, and diazepam. Complicated community-
acquired pneumonia was assumed, and piperacillin/tazobactam 
was started, together with vancomycin a few days later (Figure). 
The patient underwent pleural drainage, which was hampered 
by loculation. Pleural fluid analysis showed polymorphonuclear 
leukocytes (59.1%), low glucose (<10 mg/dL), elevated 
lactate dehydrogenase (1553 U/L), and adenosine deaminase 
(104 U/L). All fluid samples, including sputum, bronchial 
aspirate, bronchoalveolar lavage, and gastric aspirate were 
negative for acid-fast bacilli and Mycobacterium tuberculosis. 
As the patient’s clinical condition continued to worsen, 
antibiotics were stopped, and HRZE was started for suspected 
tuberculosis. Seven days later, allergists and dermatologists 
were called to assess a suspected SCAR.
The patient presented with a maculopapular rash 
and facial edema that started on the first day of HRZE, 
eosinophilia (1750/µL [baseline, 150/µL]), and acute 
kidney injury (creatinine >2 mg/mL). Fever >38ºC was 
present since admission, although this worsened after an 
initial improvement (Figure). Skin biopsy was compatible 
with a hypersensitivity reaction. No viral reactivations 
were observed (cytomegalovirus, parvovirus B19, Epstein-
Barr virus, herpes simplex virus types 1, 2, 6, and 7). The 
patient was diagnosed with DRESS syndrome (RegiSCAR 
criteria, 6) [3,6]. HRZE was stopped, and prednisolone 
1 mg/kg (60 mg) was started [7], with marked clinical and 
analytical improvement of the signs and symptoms of DRESS 
syndrome, thus allowing slow tapering of corticosteroids over 
8 weeks [7]. However, pleural fluid cultures eventually became 
positive for M tuberculosis, thus confirming the diagnosis of 
tuberculosis.
A review of the electronic clinical history showed that 
the patient was first treated with piperacillin/tazobactam for 
14 days plus vancomycin for 10 days; these drugs were then 
switched to HRZE. Although the rash started on the same day 
as HRZE, eosinophil counts >700/µL were present before 
initiation of the antituberculosis drugs. Although vancomycin 
cannot be excluded as a causative agent, the longer exposure 
time to piperacillin/tazobactam made it a more likely culprit.
Figure. Clinical parameters and drugs administered over time during 
DRESS syndrome. Blue line, fever; orange line, eosinophils; green line, 
creatinine (normal range, 0.5-1.1mg/dL). HRZE indicates isoniazid, 
rifampicin, pyrazinamide, ethambutol; DRESS, drug reaction with 
eosinophilia and systemic symptoms.
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Because the patient received HRZE for 7 days during the most 
severe phase of DRESS syndrome, the possibility of sensitization 
to these drugs in the setting of MDHS was considered [4]. The 
severity of initial respiratory symptoms meant that tuberculosis 
needed to be addressed quickly, and allergy tests were deemed 
unfeasible, as the patient was still taking prednisolone [8]. 
Therefore, we decided to reintroduce HRZE on an inpatient basis, 
1 drug at a time, with a 3-day interval between drugs, starting 
with the most urgently needed drugs. Six days after reintroduction 
of isoniazid, and 3 days after introduction of ethambutol, the 
maculopapular rash relapsed, eosinophil counts doubled to 440/
µL, and treatment was discontinued. 
Patch tests with piperacillin/tazobactam, vancomycin, 
isoniazid, ethambutol, rifampicin, and pyrazinamide were 
performed according to previously published guidelines [8,9], 
as was the lymphocyte transformation test (LTT). Patch 
test results were positive for isoniazid at 10% and 30% 
(Figure 2A, Supplementary files), and the results of LTT were 
positive (stimulation index [SI] >2) to all drugs (Figure 2B, 
Supplementary files), thus confirming MDHS [4]. 
At this point, we were faced with a patient diagnosed 
with tuberculosis and DRESS syndrome thought to have 
been induced by piperacillin/tazobactam or vancomycin. In 
addition, the situation was complicated by MDHS to HRZE 
and the fact that leaving tuberculosis untreated was not an 
option. Finally, the toxicity associated with an alternative 
HRZE-free treatment was unacceptable.
Although the LTT result was positive for all antituberculosis 
drugs tested, reevaluation of its results (Figure 2B, 
Supplementary files) made it possible to identify a higher SI 
to isoniazid and rifampicin, as well as a dose-response curve 
to both drugs, which was not present for ethambutol and 
pyrazinamide. In view of these results, an alternative schedule 
was designed; this included ethambutol, pyrazinamide, 
levofloxacin, and linezolid for 18 months. Ethionamide was 
considered but avoided based on possible cross-reactivity with 
isoniazid and a positive LTT result (SI = 11.4 plus presence of 
a dose-response curve). Drugs were planned to be introduced 
sequentially according to the ensuing “rules”, as follows: (1) 
start with one drug at a time, (2) start with the drugs posing 
a higher risk (ethambutol, pyrazinamide), (3) allow a 7-day 
interval between each new drug to clearly establish tolerance, 
and (4) start with full doses of each drug to reduce the risk of 
resistance of tuberculosis to treatment.
Ethambutol was started on day 1, pyrazinamide on day 8, 
levofloxacin on day 22, and linezolid on day 34, with delays 
caused by complaints of isolated, episodic skin pruritus. The 
patient has been successfully treated with these drugs for the 
last 12 months, with no significant adverse effects. 
In summary, we report a case of MDHS confirmed 
by positive skin and in vitro test results [4] and positive 
rechallenge with isoniazid in the setting of DRESS syndrome 
to piperacillin/tazobactam or vancomycin. Many questions 
remain unanswered with respect to our findings. Did we 
sensitize the patient to isoniazid during the first reintroduction 
attempt or was she already sensitized? Which are the best 
criteria for evaluating LTT results (SI alone vs SI plus dose-
response curves)? Despite the challenging combination 
of severe tuberculosis with DRESS and MDHS induced 
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by the main antituberculosis drugs, the judicious use of a 
combination of allergy tests and the dedicated involvement 
of a multidisciplinary team enabled the patient described 
here to successfully receive the most effective and least toxic 
treatment possible.
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